Literature DB >> 11719434

Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily.

Y Du1, T Carling, W Fang, Z Piao, J C Sheu, S Huang.   

Abstract

The retinoblastoma protein-interacting zinc finger gene RIZ1 is a tumor suppressor gene and a member of a nuclear histone/protein methyltransferase superfamily. RIZ1 inactivation is commonly found in many types of human cancers and occurs through loss of mRNA expression, frameshift mutation, chromosomal deletion, and missense mutation. RIZ1 is also a tumor susceptibility gene in mice. We now show that loss of RIZ1 mRNA in human cancers is associated with DNA methylation of its promoter CpG island. Methylation of the RIZ1 promoter strongly correlated with lost or decreased RIZ1 mRNA expression in breast, liver, colon, and lung cancer cell lines as well as in liver cancer tissues. Treatment with the methylation inhibitor 5-aza-2'-deoxycytidine activated RIZ1 mRNA expression in cancer cells. Furthermore, methylation was found in 11 of 25 (44%) breast cancer specimens and 20 of 32 (62%) liver cancer specimens. Our results suggest that DNA methylation is a common mechanism in inactivating the RIZ1 tumor suppressor gene in human liver and breast cancers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719434

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Loss of promoter methylation contributes to the expression of functionally impaired PRDM1β isoform in diffuse large B-cell lymphoma.

Authors:  Yi-Wen Zhang; Hong-Qiang Xie; Yu Chen; Bo Jiao; Zhi-Xiang Shen; Sai-Juan Chen; Wei-Li Zhao
Journal:  Int J Hematol       Date:  2010-09-22       Impact factor: 2.490

2.  Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors.

Authors:  Ivan Garcia-Bassets; Young-Soo Kwon; Francesca Telese; Gratien G Prefontaine; Kasey R Hutt; Christine S Cheng; Bong-Gun Ju; Kenneth A Ohgi; Jianxun Wang; Laure Escoubet-Lozach; David W Rose; Christopher K Glass; Xiang-Dong Fu; Michael G Rosenfeld
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

3.  Structural and functional characterization of the acidic region from the RIZ tumor suppressor.

Authors:  Yizhi Sun; Jessica M Stine; Daniel Z Atwater; Ayesha Sharmin; J B Alexander Ross; Klára Briknarová
Journal:  Biochemistry       Date:  2015-02-02       Impact factor: 3.162

Review 4.  Epigenetic changes in the myelodysplastic syndrome.

Authors:  Jean-Pierre Issa
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

5.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

Review 6.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

7.  Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.

Authors:  Chenran Zhang; Wei Meng; Jiajia Wang; Yicheng Lu; Guohan Hu; Liuhua Hu; Jie Ma
Journal:  Cell Mol Neurobiol       Date:  2016-10-18       Impact factor: 5.046

8.  PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells.

Authors:  Christopher A Davis; Michael Haberland; Michael A Arnold; Lillian B Sutherland; Oliver G McDonald; James A Richardson; Geoffrey Childs; Stephen Harris; Gary K Owens; Eric N Olson
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

9.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer.

Authors:  Mónica Castro; Laura Grau; Patricia Puerta; Liliana Gimenez; Julio Venditti; Silvia Quadrelli; Marta Sánchez-Carbayo
Journal:  J Transl Med       Date:  2010-09-17       Impact factor: 5.531

10.  RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.

Authors:  Ashakumary Lakshmikuttyamma; Naoto Takahashi; Elodie Pastural; Emina Torlakovic; Hesham M Amin; Guillermo Garcia-Manero; Michael Voralia; Magdalena Czader; John F DeCoteau; C Ronald Geyer
Journal:  J Hematol Oncol       Date:  2009-07-14       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.